MarketVIEW: Norovirus vaccines (CAT: VAMV015)

**Product Name**: MarketVIEW: Norovirus vaccines

**Description**: Global vaccine commercial opportunity assessment

**Contents**: Executive presentation + 1 forecast model

**Therapeutic Area**: Novel vaccines

**Publication date**: October 2015

**Catalogue No**: VAMV015

**Background**

Noroviruses (NVs) called “Norwalk-like viruses” are a group of single-stranded positive sense RNA viruses and members of the family *Caliciviridae*. NVs are transmitted from human-to-human and are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms usually resolving after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge. In the US, which does not yet have active national surveillance, norovirus infections may account for an estimated 1.8 million outpatient visits, 400,000 emergency department visits, 56,000–71,000 hospitalizations and 570–800 deaths. NV outbreaks are also a well-known issue for military installations and commercial cruise ship liners.

A key question for vaccine manufacturers is whether norovirus will be the next rotavirus, and so a commercial opportunity for future development. Presently there is only one known norovirus active program being developed by Takeda Pharmaceuticals currently in Phase II testing.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Norovirus across major Western and emerging markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted by a potential vaccine.
Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to norovirus epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of travel and nosocomial vaccines has also been utilised.

**PRODUCT CONTENTS:**
**Updated October 2015 (CAT No: VAMV015)**

****This product is composed of a model and summary presentation

**Contents – Summary presentation (MS PowerPoint based)**
Authors note
Contents
Executive summary
Commercial model: key outputs
Norovirus vaccines: global value ($m) to 2035 per segment
Norovirus vaccines: global value ($m) to 2035 per scenario
Norovirus vaccines: global volume (doses) to 2035 per segment
Key model parameters:
Key model parameters: scenario definitions
Forecast comparisons: June 2010 vs. October 2015
The role of a norovirus vaccine
Norovirus vaccines: target product profile
Potential markets for norovirus vaccines: LTCFs
Potential markets for norovirus vaccines: infants
Potential markets for norovirus vaccines: cruise ship passengers
Potential markets for norovirus vaccines: passenger growth
Potential markets for norovirus vaccines: HCWs
Pricing
Norovirus: background and epidemiology
Norovirus: media coverage
The pathogen
Norovirus: genogroup classifications
Disease burden
Norovirus and diarrheal disease worldwide
Estimates of annual burden (US)
Impact in Infants
Infants: US hospitalization rates
NoV incidence and infection from a birth cohort in a Peruvian community
Cruise ships and norovirus
Cruise ships: norovirus outbreaks
Long-term care facilities and norovirus
Long-term care facilities: comparison to other settings
Healthcare settings
Challenges with estimating norovirus disease burden
Continued…..

Norovirus and diagnostics
Norovirus and subclinical disease
Norovirus and chronic health consequences
Norovirus infection and genetic susceptibility
Norovirus vaccines: background and rationale
Stakeholder messages: need for vaccines
Natural immunity to norovirus
The role of a norovirus vaccine
Norovirus vaccines: target product profile
Target group considerations for a norovirus vaccine
Norovirus: correlates of immune protection
Challenges to norovirus vaccine development
Norovirus vaccines: R&D pipeline
Development status of current vaccine candidates
Norovirus vaccine pipeline: Takeda
Takeda GI.1, GII.4 cVLP: Phase I results
Takeda GI.1, GII.4 cVLP: Phase II results
Takeda: ongoing Phase II program
Takeda: duration of protection
Norovirus vaccine pipeline: Takeda
Norovirus vaccine pipeline: Phase II results
Norovirus vaccine pipeline: other vaccines
Bibliography

About VacZine Analytics
Disclaimer

PAGES: 64 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Charts
VALUE SUMMARY – total market
VOLUME SUMMARY – total market
US lo/base/hi
Canada lo/base/hi
UK lo/base/hi
France lo/base/hi
Germany lo/base/hi
Italy lo/base/hi
Spain lo/base/hi
EU other lo/base/hi
Australia lo/base/hi
Total population
Births
>65 yrs
Pricing summary
Pub/priv split
Cruise ship passengers
Continued…..

Cruise ship outbreaks
HCWs
Pipeline
Country income group
Disclaimer
BACK PAGE

WORKSHEETS: ~25
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00/ GBP £5995.00* (Region license)*

* Indicative rate only. Prevailing rate applied to date of transaction.
* A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY:

TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009

@VACZINEANALYTIC